ICON Stock Surges 17% Above All Analyst Targets
ICON Public Limited Company jumped 17% on October 29 after reporting a 1.1% EPS beat and raising full-year guidance, pushing shares above every published analyst target. The question investors face is
ICON Q3 Beat Sends ICLR Up 17% Past Analyst Targets
NEW YORK, October 29 —
ICON Public Limited Company (ICLR) surged 17.04% to $214.16 on October 29 after Q3 earnings beat and a 2026 guidance raise, pushing shares past both the consensus analyst target of $188.24 and a freshly raised 12-month target of $200.81. The move leaves investors to judge whether the guidance raise justifies a price no published model had reached.
- Q3 EPS of $2.66 beat the $2.63 consensus by 1.1%; the full-year guidance raise drove the single-session move.
- Consensus analyst target of $188.24 and a freshly raised 12-month target of $200.81 both sit below the $214.16 close.
- Insiders recorded $4.02 million in net open-market sales and zero purchases over the prior 90 days.
How a 1.1% Beat Became a 17% Move
The EPS beat was incremental ($2.66 against a $2.63 estimate) but arrived alongside backlog data analysts called impressive and a full-year guidance raise the market read as a significant revision. ICON runs Phase I-IV clinical trials, data solutions, and laboratory services for pharmaceutical, biotech, and government clients, generating $8.29 billion in trailing revenue at 1.2% annual growth. The earnings trajectory matters: four quarters ago, ICON reported a severe miss ($2.52 against a $3.11 estimate), then ground out three consecutive beats of 2.9%, 1.6%, and 1.1%. The guidance raise accompanying those beats pushed shares above every published analyst target in a single session.
A Price With No Analyst Cover
At $214.16, ICLR trades above every published 12-month price target. The Street's consensus of $188.24 sits approximately 12% below the close, and a freshly raised target of $200.81 citing 10% implied upside was overtaken the same day it appeared. ICON carries $3.53 billion in total debt against $0.93 billion in cash at a forward P/E of 18.2x, a leverage position partly offset by $623 million in trailing free cash flow; investors wanting to pressure-test the guidance raise's implied assumptions can use the DCF calculator. Whether the guidance raise justifies a premium to every published target is what the next quarterly report will answer.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| ICLR | $16.5B | 18.3x | +29.1% |
| CRL | $17.9B | 29.3x | +107.6% |
| IQV | $46.0B | 19.6x | +28.1% |
| MEDP | $19.4B | 34.9x | +18.5% |
| BRKR | $9.4B | 25.8x | +64.3% |
| WST | $28.4B | 40.4x | +41.7% |
Insiders Who Sold at $175
Three ICON directors (John Climax, Ronan Murphy, and Eugene McCague) sold a combined 13,265 shares at $175 per share in September, following same-day option exercises at a $125.74 strike price, per SEC filings. Smaller August sales by the CFO and a director brought the 90-day insider total to $4.02 million in sales against zero purchases. Exercise-and-sell transactions often reflect option schedules rather than a directional view; the relevant watch is whether the next filing cycle shows purchases at the current price. Run the free ICON Public Limited Company deep-dive → for current metrics.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did ICON stock jump 17%?
ICON stock surged 17% to $214.16 on October 29 following Q3 earnings that beat consensus by 1.1% (EPS $2.66 vs. $2.63) and a full-year guidance raise. The guidance increase, combined with what analysts called impressive backlog data, drove the move.
Does ICON's stock price exceed analyst targets?
Yes. At $214.16, shares trade above both the consensus analyst target of $188.24 and a freshly raised 12-month target of $200.81. This leaves investors to judge whether the guidance increase justifies the valuation premium above all published models.
What is ICON's debt level?
ICON carries $3.53 billion in total debt against $0.93 billion in cash, resulting in a leveraged balance sheet. The company generated $623 million in trailing free cash flow, providing some offset to the debt burden at a forward P/E of 18.2x.
Did ICON insiders buy at these prices?
No. Over the prior 90 days, insiders recorded $4.02 million in net sales and zero purchases. Three directors sold shares at $175 in September following option exercises, a pattern typically reflecting option schedules rather than conviction about the stock's direction.
What does ICON Public do?
ICON runs Phase I-IV clinical trials, data solutions, and laboratory services for pharmaceutical, biotech, and government clients. The company generated $8.29 billion in trailing revenue at 1.2% annual growth, reflecting a mature, stable business.
ICON plc stock surged 17.04% to $214.16 on October 29 after the clinical research organization beat Q3 earnings estimates and raised its 2026 full-year guidance — but the move has pushed shares past both the consensus analyst target of $188.24 and a freshly raised 12-month target of $200.81, while every insider who sold over the prior three months did so at prices well below today's level.